{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-22-024000","form_type":"8-K","ticker":"HURA","cik":"0001498382","company_name":"TuHURA Biosciences, Inc./NV","filed_at":"2022-11-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:50.864114+00:00","generated_at":"2026-06-22T01:08:03.588531+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Kintara Q1 net loss $4.6M; pauses REM-001 to save $3M, continues VAL-083 trial","bullets":["Net loss of $4.6M ($0.07/share) for quarter ended Sep 30, 2022, vs $6.0M ($0.25) a year ago.","Cash and equivalents $7.1M at Sep 30, down from $11.8M at Jun 30; net $1.9M from Lincoln Park equity line.","Paused REM-001 CMBC program to conserve cash; expects to save ~$3.0M through 2023.","VAL-083 GBM AGILE registrational study ongoing; top-line data expected around end of 2023.","Entered $20M purchase agreement with Lincoln Park Capital; $1.9M received as of Nov 8."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-22-024000","json":"https://secwatch.observer/filing/0000950170-22-024000.json","markdown":"https://secwatch.observer/filing/0000950170-22-024000.md","text":"https://secwatch.observer/filing/0000950170-22-024000.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1498382/000095017022024000/0000950170-22-024000-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1498382/000095017022024000/ktra-20221109.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-22T01:08:03.588531+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"1b7fa5885d5766bbaca8c4ac12728dabf43ea64c","claim":"TuHURA Biosciences, Inc./NV reported the three months ended September 30, 2022 results: net income net loss of approximately $4.6 million, or $0.07 per share, EPS $0.07 per share.","evidence_excerpt":"For the three months ended September 30, 2022, Kintara reported a net loss of approximately $4.6 million, or $0.07 per share, compared to a net loss of approximately $6.0 million, or $0.25 per share, for the three months ended September 30, 2021.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1498382/000095017022024000/0000950170-22-024000-index.htm","confidence":1.0,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the three months ended September 30, 2022"},{"label":"Net income","value":"net loss of approximately $4.6 million, or $0.07 per share"},{"label":"EPS","value":"$0.07 per share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}